ストックスクリーナーアプリを入手
3.03
3.50%
-0.11
前日終値:
$3.14
開ける：
$3.23
24時間の取引高:
2.34M
Relative Volume:
0.72
時価総額：
$894.96M
収益：
$38.03M
当期純損益:
$-146.40M
株価収益率:
-5.8269
EPS:
-0.52
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
-7.34%
1か月 パフォーマンス:
-0.98%
6か月 パフォーマンス:
+14.77%
1年 パフォーマンス:
-37.01%
1日の値動き範囲:
$3.03
$3.2301
1週間の範囲:
$3.03
$3.60
52週間の値動き範囲:
$2.335
$5.26
Abcellera Biologics Inc Stock (ABCL) Company Profile
ABCL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.03 | 894.96M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
AbCellera reassigns COO to CTO role, dissolves position - Investing.com India
AbCellera Biologics Changes COO's Title to Technology Chief -February 18, 2025 at 12:57 pm EST - Marketscreener.com
AbCellera reassigns COO to CTO role, dissolves position By Investing.com - Investing.com South Africa
One AbCellera Biologics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Update - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
AbCellera Biologics (ABCL) to Release Earnings on Tuesday - MarketBeat
Moloney Securities Asset Management LLC Takes $265,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Time to Sell? - MarketBeat
AbCellera to Participate at Upcoming Investor Conferences in March - The Globe and Mail
Biotech in B.C. battles harsh market while landing big deals - Business in Vancouver
AbCellera Biologics (NASDAQ:ABCL) Shares Down 4%Here's Why - MarketBeat
AbbVie, AbCellera expand collaboration into T-cell engagers - MSN
ABCL (AbCellera Biologics) Shares Outstanding (EOP) : 295.16 Mil (As of Sep. 2024) - GuruFocus.com
JPMorgan Chase & Co. Acquires 21,483 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics (NASDAQ:ABCL) Shares Up 18.8%Here's What Happened - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8%Here's What Happened - MarketBeat
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - BioSpace
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29% - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7%What's Next? - MarketBeat
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5%What's Next? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.7%Here's Why - MarketBeat
Geode Capital Management LLC Sells 201,213 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
Geode Capital Management LLC Has $295,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - sharewise
AbCellera and AbbVie expand oncology collaboration - Investing.com
AbCellera and AbbVie expand oncology collaboration By Investing.com - Investing.com South Africa
KeyCorp Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World
AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $4.00 by Analysts at KeyCorp - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9%What's Next? - MarketBeat
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? - Insider Monkey
12 Best Canadian Penny Stocks to Buy According to Analysts - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7.2%Time to Buy? - MarketBeat
Stifel Financial Corp Has $195,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6%What's Next? - MarketBeat
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):